Abstracts tagged "gout"

Abstract Number: 0682 • ACR Convergence 2021
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Jasvinder Singh¹ and N Lawrence Edwards², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Florida College of Medicine, Gainesville, FL
Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life…
Abstract Number: 1575 • ACR Convergence 2021
Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response
Anyan Cheng¹, Isidoro Cobo¹, Jessica Murillo Saich¹, Roxana Coras², Alyssa Torres³, Addison Lana¹, Johannes Schlachetzki¹, Ru Liu Bryan⁴, Robert Terkeltaub⁵, Elsa Sanchez-Lopez³, Christopher Glass¹ and Monica Guma⁶, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³University of California San Diego, San Diego, CA, ⁴University of California San Diego and VASDHS, San Diego, CA, ⁵VA/UCSD, San Diego, CA, ⁶University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Although metabolic reprograming and its regulation in macrophages after TLR activation is well established, little is known about the regulation and the role of…
Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0535 • ACR Convergence 2020
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
Jasvinder Singh¹, John Richards², Elizabeth Chang³, Toupin-April, Karine Toupin-April⁴ and Jennifer Barton⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ³Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, ⁴VA Portland Oregon, Portland, OR, ⁵Oregon University, Portland, OR
Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…
Abstract Number: 0660 • ACR Convergence 2020
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Seoyoung Kim³ and Tuhina Neogi², ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ²Boston University School of Medicine, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are anti-diabetic drugs that have a urate-lowering effect. SGLT2-i had a more favorable impact on gout risk than glucagon-like peptide-1…
Abstract Number: 0682 • ACR Convergence 2020
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout
Fatima Alduraibi¹, Karina Ricart¹, Rakesh Patel¹, Alexander Szalai¹, Joshua Melnick² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Vestavia Hills, AL
Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…
Abstract Number: 1472 • ACR Convergence 2020
Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization
Natalie McCormick¹, Mark O'Connor¹, Shelby Marozoff², John Choi³, Aaron Leong¹ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, Canada, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear. Observational studies have reported positive associations…
Abstract Number: 0600 • ACR Convergence 2020
Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
Daniel DeMizio¹, Guojing Wu², Ying Wei², Joan Bathon³ and Runsheng Wang⁴, ¹Columbia University Irving Medical Center, Division of Rheumatology, Staten Island, NY, ²Columbia University Mailman School of Public Health, Department of Biostatistics, New York, NY, ³Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Columbia University Irving Medical Center, Division of Rheumatology, New York, NY
Background/Purpose: There is growing evidence that both the prevalence of gout and its burden on healthcare costs has increased over recent decades. It has been…
Abstract Number: 0662 • ACR Convergence 2020
Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%. While gout flares…
Abstract Number: 0683 • ACR Convergence 2020
Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate
Yang Song¹, Yan Xin¹, Michael Weinblatt², Jason Chamberlain¹, Katie Obermeyer³, Lin Zhao³, Colleen Canavan³, Paul Peloso⁴ and Srini Ramanathan¹, ¹Horizon Therapeutics plc, South San Francisco, CA, ²Brigham and Women's Hospital, Boston, MA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Horizon Therapeutics plc, Gurnee, IL
Background/Purpose: In an open-label trial in adult patients with uncontrolled gout (MIRROR open-label [OL] trial) evaluating pegloticase co-treatment with methotrexate (MTX), 78.6% patients maintained serum…
Abstract Number: 1542 • ACR Convergence 2020
The Role of Dual Energy Computed Tomography (DECT) in the Differentiation of Gout and Calcium Pyrophosphate Deposition Disease
Dmitrij Kravchenko¹, Pantelis Karakostas², Peter Brossart³, Charlotte Behning⁴, Carsten Meyer¹ and Valentin Schaefer⁵, ¹Department of Interventional and Diagnostic Radiology, University Hospital Bonn, Bonn, Germany, Bonn, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, Bonn, Germany, ³Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁵Clinic ofInternal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, Bonn, Germany
Background/Purpose: Differentiation of gout and calcium pyrophosphate deposition disease (CPPD) is sometimes difficult as patients often present with a similar clinical picture. Arthrocentesis and subsequent…
Abstract Number: 0646 • ACR Convergence 2020
“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television
Rachel Murdoch¹, Christina Derksen², Keith Petrie¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Jacobs University, Bremen, Germany
Background/Purpose: Views about gout as a self-inflicted condition of dietary excess can contribute to stigma and lead to ineffective management strategies. Fictional portrayals of illness…
Abstract Number: 0663 • ACR Convergence 2020
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
Nicholas Sumpter¹, Murray Cadzow², Alexander So³, Richard Reynolds¹ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Lausanne, Lausanne, Switzerland
Background/Purpose: This study aimed to estimate the extent to which gout associated genetic variants are associated with the presence/absence of common comorbidities in gout patients…
Abstract Number: 0684 • ACR Convergence 2020
The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy
Thomas Bardin¹, Nguyen Dinh Quang², Hieu Le Nghia², Tran Minh Khoi², Hang Korng EA³, Valérie Bousson⁴ and Pascal Richette⁵, ¹Université de Paris, INSERM U1132 and Hôpital Lariboisièe, Paris, France, Paris, France, ²Vien Gut Medical Center, Ho Chi Minh City, Vietnam, ³Universite de Paris, AP-HP, INSERM, paris, France, ⁴Lariboisière Hospital, Paris, France, ⁵Department of Rheumatology, Lariboisière Hospital, Paris, France
Background/Purpose: Serum urate (SU) lowering has been reported to improve gout erosions. We observed that it may also lead to compaction of toe MTP or…
Abstract Number: 1550 • ACR Convergence 2020
Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study
Tristan Pascart¹, Pascal Richette², Sebastien Ottaviani³, Laurène Norberciak¹, Hang Korng EA⁴, Frédéric Lioté⁵, Jérémy Ora⁶, Julie Legrand¹, Valérie Bousson⁶, Elyas Mahdjoub⁷ and Jean--Francois Budzik⁸, ¹GHICL, Lomme, France, ²Department of Rheumatology, Lariboisière Hospital, Paris, France, ³Rheumatology Department, Bichat hospital, APHP, Paris, France, ⁴Universite de Paris, AP-HP, INSERM, paris, France, ⁵AP-HP, Paris, France, ⁶Lariboisière Hospital, Paris, France, ⁷Bichat Hospital, Paris, France, ⁸University of Lille, Lille, France
Background/Purpose: Dual-Energy computed tomography (DECT) and ultrasound are the two techniques able to identify and measure monosodium urate (MSU) crystal deposition, and both are considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].